StockData

Mineralys Therapeutics vs Rein Therapeutics

MLYS and RNTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MLYS and RNTX compare

Mineralys Therapeutics is the larger company, worth 42 times as much as Rein Therapeutics ($1.3B against $30.7M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMLYSRNTX
Size and price
Market cap$1.3B$30.7M
Share price$14.48$0.356
Change, 1 year−64.6%−71.5%
Change, 5 years–−97.3%
Beta (5Y)2.452.30
Employees7610
StockData Score
Total score66
Valuation score01 (better)
Growth score00
Performance score00
Health score6 (better)5
Dividend score00
Valuation
P/B2.3×0.6× (better)
Profitability
Return on equity−80.9% (better)−96.4%
Return on invested capital−93.8% (better)−145%
Financial health
Debt / equity0.000.00
Current ratio34.46 (better)4.27
Altman Z-score4.35 (better)−8.96
Piotroski F-score4 (better)2
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield–−179%
Shareholder yield0.00% (better)−179%
Ownership
Held by institutions114%47.3%
Held by insiders24.1%9.6%
Insider net buying, 12 months−$19.2M$74.7K (better)
Short interest, % of float11.5%0.91%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.